NCT03332511View on ClinicalTrials.gov

Efficacy and Safety of Nilotinib in CML-CP

PHASE4CompletedINTERVENTIONAL

Enrollment

110

Participants

Timeline

Start Date

May 6, 2013

Primary Completion Date

October 24, 2016

Study Completion Date

October 24, 2016

Conditions

Chronic Myeloid Leukemia, Chronic Phase

Interventions

DRUG

Nilotinib

Nilotinib 300mg twice-daily

Sponsors

Collaborators (1)

Novartis Pharmaceuticals

All Listed Sponsors

collaborator

Novartis Pharmaceuticals

INDUSTRY

lead

Seoul National University Hospital

OTHER